Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Exopharm Limited
  6. News
  7. Summary
    EX1   AU0000030975

EXOPHARM LIMITED

(EX1)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Exopharm Limited Announces Further Step Towards Granted US Patent for its LEAP Technology

09/26/2021 | 06:24pm EST

Exopharm Limited has made a further step towards a granted US Patent for its LEAP technology. Exopharm has been alerted to the web site of the United States Patent and Trademark Office (USPTO) about the company's LEAP patent application and the further progress of that patent application (Application 17/147,033) (Application) under the United States National Phase. Upon inspection, the USPTO web site shows that the Examiner has upgraded the Application to `Notice of Allowance Mailed', indicating that the Examiner has accepted recent amendments to the Application, sees the Application as meeting their requirements and is ready to issue the requested patent (subject to some further steps and payment of fees). At this point a USPTO patent number has not been issued in relation to the Application and there are some formalities that need to be completed. Normally the US Patent would be issued around 8 weeks after the marked publication date (date which has not yet been set) and the payment of a fee by the Company to the USPTO. Upon publication the Application is open to objections by other parties. Normally the Company would make an announcement - giving patent number, the expiry date and its importance - upon the final grant of a patent, immediately upon completion. However, the Company wanted to ensure that this information was broadly available.


ę S&P Capital IQ 2021
All news about EXOPHARM LIMITED
2021Exopharm Gets US Patent for Drug Delivery Technology
MT
2021Exopharm Limited Appoints David Franks as Company Secretary
CI
2021Exopharm Limited Announces Further Step Towards Granted US Patent for its LEAP Technolo..
CI
2021Exopharm Limited Appoints Jennifer King to the Board, Effective 1 September 2021
CI
2021EXOPHARM : Widens After-Tax Loss in FY21; Shares Jump 6%
MT
2021Exopharm Limited Reports Earnings Results for the Full Year Ended June 30, 2021
CI
2021EXOPHARM : Raises Over $9 Million for Technology Platform Commercialization; Shares Fall 9..
MT
2021EXOPHARM : Completes Phase One Safety Trial for Extracellular Vesicle-Derived Medication
MT
2021Exopharm Limited Signs Non-Binding Heads of Agreement with the Finnish Red Cross Blood ..
CI
2021Exopharm Limited Announces Positive PLEXOVAL II Phase 1 Clinical Trial Results with Off..
CI
More news
Financials
Sales 2021 4,19 M 3,01 M 3,01 M
Net income 2021 -8,47 M -6,09 M -6,09 M
Net cash 2021 11,4 M 8,17 M 8,17 M
P/E ratio 2021 -8,64x
Yield 2021 -
Capitalization 73,1 M 52,7 M 52,6 M
EV / Sales 2020 8,64x
EV / Sales 2021 18,3x
Nbr of Employees 41
Free-Float -
Chart EXOPHARM LIMITED
Duration : Period :
Exopharm Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXOPHARM LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Managers and Directors
Ian Dixon Chief Executive Officer, Director & MD
Jason Watson Non-Executive Chairman
Gregor Lichtfuss Chief Operating Officer
Jennifer King Independent Non-Executive Director
Elizabeth McGregor Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
EXOPHARM LIMITED-9.62%53
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%53 950
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068
ICON PUBLIC LIMITED COMPANY-13.98%21 684